$500 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 53 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -152,345 | -100.0% | -0.13% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INC | $0 | – | -59,122 | -100.0% | -0.27% | – |
| CALT | Exit | CALLIDITAS THERAPEUTICS ABsponsored adr | $0 | – | -100,000 | -100.0% | -0.50% | – |
| RDUS | Exit | RADIUS HEALTH INC | $0 | – | -763,888 | -100.0% | -1.06% | – |
| BGNE | Exit | BEIGENE LTDsponsored adr | $0 | – | -20,000 | -100.0% | -1.09% | – |
| ODT | Exit | ODONATE THERAPEUTICS INC | $0 | – | -12,767,435 | -100.0% | -3.47% | – |
| CCXI | Exit | CHEMOCENTRYX INC | $0 | – | -500,000 | -100.0% | -3.66% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
| LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
| ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
| ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
| COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
| EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
| RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
| MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 4 | 2024-02-02 |
| 4 | 2023-12-18 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-13 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-06-01 |
| 4 | 2023-06-01 |
| 4 | 2023-05-30 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.